HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Lack of elderly patients in cancer trials leads to inadequate treatment guidance
-
- Heart surgery increases mortality risk for cancer survivors who had radiation
- Physicians receive Taubman Prize
- A 45-year-old man develops pancytopenia and brain lesions Ramya Varadarajan, MD
- FDA grants priority review for Perjeta as neoadjuvant treatment of HER-2–positive breast cancer
- FDA approves Gilotrif for late-stage NSCLC
- FDA approves Rixubis for hemophilia B
- FDA approves Sensus Healthcare’s SRT-100 for keloid treatment
- Medicaid programs vary in coverage of preventive care
-
- Intercalated chemotherapy plus erlotinib effective for EGFR-positive NSCLC
- ‘Female advantage’ persists in stage III/IV metastatic melanoma
- Aryl hydrocarbon receptor may play role in red blood cell development
- Ibrutinib yields encouraging outcomes in CLL
- Low-dose decitabine shows promise in myelodysplastic syndrome
- Nearly all childhood cancer survivors develop chronic health conditions
- Active surveillance appears unsuitable for black men with prostate cancer
- Agent Orange exposure may increase prostate cancer risk
-
- Allogeneic HSCT improved outcomes for children with relapsed ALL
- Bacteremia risk low in febrile sickle cell disease patients
- Extended adjuvant letrozole benefitted women with high HOXB13/IL17BR biomarker index
- False FIT results common with small, nonpolypoid colorectal adenomas, early cancer
- High-dose liposomal daunorubicin extended survival in pediatric AML
- IPD incidence rate decreased among children with sickle cell disease
- Lenalidomide active in peripheral T-cell lymphoma
- Long-term cancer survivors at greater risk for anxiety than depression
-
- New oral anticoagulants may increase GI bleeding risk
- Only half of physicians follow cervical cancer prevention guidelines
- Patients with invasive CSCC displayed risk factors for metastasis, death
- Potential cancer risk from CT decreased parental willingness to test
- Preliminary results suggest safety, efficacy of tremelimumab as HCC, HCV therapy
- Psychological, physical impairments typical after cancer diagnosis
- Red meat consumption associated with greater risk for esophageal cancer
- Survival comparable between preoperative, perioperative chemotherapy in early-stage NSCLC
-
- ER-positive, PR-positive breast cancer linked to increased risk for secondary primary cancer
- Local reactivity, biomarkers predict response to autologous melanoma vaccine
- Collaboration essential to rapid transfer of knowledge from trial to clinical practice
- Osteoporosis drug may have clinical activity in breast cancer
- Expert sheds light on advances in thyroid cancer diagnosis, therapy
- Novel TKI shows promise in ALK-positive patients
- Oncolytic immunotherapy improved durable response, survival in metastatic melanoma
- ORIGIN: Cancer incidence, mortality rates unaffected by insulin glargine
-
- WINTHER trial seeks to select rational therapeutics based on analysis of tumor without DNA structural changes
- Plasma micro-RNA levels may predict response to cetuximab plus FOLFIRI
- Sequence does not alter benefit of sorafenib-sunitinib combination in renal cell carcinoma
- IMRT plus chemotherapy offers high locoregional control in advanced nasopharyngeal carcinoma
- Comprehensive genome sequencing should be considered for advanced cancers to identify actionable gene mutations
- The evolving role of arsenic trioxide in the treatment of APL Debbie Blamble, PharmD, BCOP